Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
MiNK Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 15,001 shares
@ $1.0919, valued at
$16.4k
|
|
| 10/03/2023 |
4
| Buell Jennifer (CEO) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 25,000 shares
@ $1.1538, valued at
$28.8k
Paid exercise price by delivering 58,550 shares
@ $1.0445, valued at
$61.2k
Paid exercise price by delivering 65,000 shares
@ $0.9449, valued at
$61.4k
|
|
| 09/29/2023 |
4
| Buell Jennifer (CEO) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Exercised 695,750 restricted stock units
@ $0 |
|
| 08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/16/2023 |
4
| Behner Peter (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $2.27, valued at
$51.1k
|
|
| 06/16/2023 |
4
| Ryan Barbara (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 37,500 options to buy
@ $2.27, valued at
$85.1k
|
|
| 06/16/2023 |
4
| Corvese Brian (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 37,500 options to buy
@ $2.27, valued at
$85.1k
|
|
| 06/16/2023 |
4
| Baldoni John (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $2.27, valued at
$51.1k
|
|
| 06/16/2023 |
4
| WIINBERG ULF (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 22,500 options to buy
@ $2.27, valued at
$51.1k
|
|
| 06/02/2023 |
4
| Corvese Brian (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 10,157 shares
@ $1.76, valued at
$17.9k
|
|
| 06/02/2023 |
4
| Ryan Barbara (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 10,086 shares
@ $1.76, valued at
$17.8k
|
|
| 06/02/2023 |
4
| Behner Peter (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 8,736 shares
@ $1.76, valued at
$15.4k
|
|
| 06/02/2023 |
4
| WIINBERG ULF (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 7,955 shares
@ $1.76, valued at
$14k
|
|
| 06/02/2023 |
4
| Baldoni John (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 8,168 shares
@ $1.76, valued at
$14.4k
|
|
| 05/26/2023 |
4/A
| ARMEN GARO H (Director) has filed a Form 4 on MiNK Therapeutics, Inc. |
| 05/26/2023 |
4/A
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc. |
| 05/26/2023 |
4/A
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Disposed of 5,006,397 shares
@ $0 |
|
| 05/26/2023 |
SC 13D/A
| AGENUS INC reports a 62.5% stake in MINK THERAPEUTICS, INC. |
| 05/12/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 22,065 shares
@ $1.509, valued at
$33.3k
Bought 23,361 shares
@ $1.4275, valued at
$33.3k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 128,689 shares
@ $1.0789, valued at
$138.8k
Bought 21,473 shares
@ $1.2223, valued at
$26.2k
Bought 100,000 shares
@ $0.9485, valued at
$94.9k
Bought 200 shares
@ $1.25, valued at
$250 |
|
| 05/04/2023 |
4
| ARMEN GARO H (Director) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Bought 100,000 shares
@ $0.9485, valued at
$94.9k
|
|
| 05/03/2023 |
4
| AGENUS INC (10% Owner) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Disposed of 4,988,273 shares
@ $0 |
|
| 05/03/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/21/2023 |
8-K
| Quarterly results|
Docs:
|
"MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results NEW YORK, March 21, 2023 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022. “2022 has been an important year for MiNK, with significant progress across our clinical and preclinical programs in iNKT cell therapy, bolstered by the expansion of our in-house manufacturing capabilities," stated Dr. Jennifer Buell, President and Chief Executive Officer of MiNK. "Our advancements have solidified MiNK's position as a leader in the iNKT cell the..." |
|
| 01/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/12/2023 |
4
| van Dijk Marcus Antonius (Chief Scientific Officer) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 51,628 shares
@ $2.32, valued at
$119.8k
Paid exercise price by delivering 24,265 shares
@ $2.32, valued at
$56.3k
|
|
| 01/11/2023 |
4
| van Dijk Marcus Antonius (Chief Scientific Officer) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 15,000 options
@ $2.32, valued at
$34.8k
|
|
| 01/11/2023 |
4
| Buell Jennifer (CEO) has filed a Form 4 on MiNK Therapeutics, Inc.|
Txns:
| Granted 171,990 shares
@ $2.32, valued at
$399k
Granted 500,000 options
@ $2.32, valued at
$1.2M
|
|
|
|
|